Jan 7, 2015 – Sera Prognostics announced that it has closed $20 Million in Series B financing, led by Chione, Ltd, a European investment company, and appointed Mansoor Raza Mirza, M.D. to its Board of Directors.
Feb 24, 2015–Sera Prognostics announced that Arnold L. Oronsky, Ph.D., General Partner at InterWest Partners, LLC, was appointed to its Board of Directors. Dr. Oronsky’s addition to the Sera board occurs as the company is in the final stages of developing PreTRM™, its novel proteomic predictor for preterm birth risk, prior to its commercial launch. In addition, Douglas Fisher, M.D., joins the company’s management team as Chief Business Officer.
Feb 4, 2015-Sera Prognostics announced that the Bill & Melinda Gates Foundation has agreed to join the Company’s Series B financing, which will bring the total transaction to $25 million. The additional funding will help Sera expand the reach of its proteomic technology, to develop new tests designed to predict the risk of preterm birth for women in developing countries around the world.